Dey et al. [73] reported that in SMAD4-mutated PDAC, the loss of the neighbouring housekeeping gene malic enzyme 2 (ME2) in these tumours, created a cancer-specific metabolic vulnerability to Malic Enzyme 3 (ME3) inhibition. This evidence concerns the gene ME3 and cancer.